Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations


January 24, 2019
JCI Insight

Scientists at JHU showed that there is an intra-tumor and inter-patient heterogeneity to drug responses in patient-derived primary liver organoids. These studies indicate the potential use of pre-clinical organoid models in screening small-molecules and identifying novel targets.

January 16, 2019
Nature Communications

OHSU CTD2 scientists identify distinct patterns of mutation dynamics during FLT3 inhibitor, crenolanib treatment in acute myeloid leukemia. This study indicates comprehensive sequencing should be carried before and during the treatment to identify combinatorial agents and prevent drug resistance.

January 10, 2019

Study identifies networks of DNA damage-up proteins that may predict tumorigenic functions of cancer-promoting proteins.

January 07, 2019
PLoS One

CTD2 researchers developed phospho-proteomic specific algorithm, pARACNe, which measures phospho-state dependencies between tyrosine kinases and their candidate substrates from large-scale LC-MS/MS phosphoproteomic profiles.

January 07, 2019

Scientists from BLGSP demonstrated that tumor EBV status defines a specific BL phenotype irrespective of geographic origin with particular molecular properties and distinct pathogenic mechanisms. EBV-positive BL genomes feature fewer driver mutations despite their greater mutational load.

January 01, 2019
Nature Medicine

UCSF (1) CTD2 researchers identified a synthetic lethal interaction between EGFR tyrosine kinase inhibitors and Aurora kinase inhibitors in acquired resistant cells. This study suggests combinatorial treatment to prevent treatment resistance with the monotherapies.

December 26, 2018
Cell Systems

Bioinformatic approach, Similarity Weighted Nonnegative Embedding (SWNE), enables visualization of single-cell gene expression data into biologically relevant factors.

December 24, 2018

UCSD study suggests that the combination of APOBEC-related mutagenesis and tumor mutation burden may be used as a biomarker of response to immunotherapy.

December 21, 2018

Analysis of next generation sequencing of patients with hematologic malignancies showed that patients had alterations that could be targeted with gene or immune-targeted therapies.